Phaseline

Companies › Innovent Biopharmaceutical Technology (Hangzhou)

Innovent Biopharmaceutical Technology (Hangzhou): clinical trials, targets and expected readouts

7 active drug programs in 178 registered trials: 140 Phase 2, 20 Phase 3, 18 Phase 1; Oncology, Immunology, Infectious disease; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Picankibart–Phase 3Plaque Psoriasis; Psoriatic ArthritisJan 2027
IBI354
Anti-HER2 antibody
ERBB2Phase 3HER2-positive Breast CancerApr 2028
IBI112
IL-23 inhibitor
IL23APhase 3PsoriasisJan 2029
IBI310
CTLA-4 inhibitor
CTLA4Phase 2Hepatocellular Carcinoma (HCC); Neuroendocrine Neoplasm; Gastric CancerDec 2027
Sintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 2Hepatocellular Carcinoma (HCC); Resectable Gastric/Gastroesophageal Junction Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Squamous Cell Non-small Cell Lung Cancer …Dec 2027
Ipilimumab (N01)
Cytotoxic T-lymphocyte protein 4 inhibitor
CTLA4Phase 2Resectable Gastric/Gastroesophageal Junction AdenocarcinomaDec 2031
IBI3028
Recombinant anti-EGFR and c-Met antibodies dual-payload conjugate
EGFR, METPhase 1Solid TumorJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03869034SintilimabPhase 2Hepatocellular CarcinomaOncologyJul 2020
NCT03869034SintilimabPhase 2Hepatocellular CarcinomaOncologyJul 2020
NCT04940546SintilimabPhase 1Colorectal Cancer MetastaticOncologyOct 2023
NCT05177068SintilimabPhase 2Gastric CancerOncologyOct 2024
NCT06808412SintilimabPhase 2Rcctal CancerOncologyMay 2025
NCT06787911SintilimabPhase 2Thyroid CancerOncologyMay 2025
NCT04295317SintilimabPhase 2Intrahepatic CholangiocarcinomaOncologyJun 2025
NCT06776757SintilimabPhase 1Metastatic Colorectal CancerOncologyJun 2025
NCT06054906SintilimabPhase 2Gastric CancerOncologyJun 2025
NCT05010681SintilimabPhase 2Intrahepatic CholangiocarcinomaOncologyAug 2025
NCT06718205SintilimabPhase 2Esophageal CancerOncologySep 2025
NCT05165407SintilimabPhase 2Neuroendocrine NeoplasmOncologySep 2025
NCT05165407IBI310Phase 2Neuroendocrine NeoplasmOncologySep 2025
NCT05098847SintilimabPhase 2Liver MetastasisOncologyOct 2025
NCT06583083SintilimabPhase 2Natural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeOncologyAug 2026
NCT06759064SintilimabPhase 1Cancer of Stomach, AdenocarcinomaOncologySep 2026
NCT05057052SintilimabPhase 2Liver MetastasesOncologySep 2026
NCT06356584SintilimabPhase 2Colorectal CancerOncologyOct 2026
NCT07750951SintilimabPhase 2MSI-H/dMMR Locally Advanced Rectal AdenocarcinomaOncologyNov 2026
NCT06563869SintilimabPhase 3Esophageal Squamous Cell CarcinomaOncologyNov 2026
NCT06091423SintilimabPhase 2Gastric Cancer/Gastroesophageal Junction AdenocarcinomaOncologyNov 2026
NCT05429463SintilimabPhase 3Squamous Cell Non-small Cell Lung CancerOncologyNov 2026
NCT06767007SintilimabPhase 2Unresectable Locally Recurrent Rectal CancerOncologyNov 2026
NCT04512534SintilimabPhase 2Peripheral T-cell LymphomaOncologyDec 2026
NCT04512534SintilimabPhase 2Peripheral T-cell LymphomaOncologyDec 2026
NCT06714708SintilimabPhase 2NSCLCOncologyDec 2026
NCT05593458SintilimabPhase 3Locally Advanced Gastric CarcinomaOncologyDec 2026
NCT05918094SintilimabPhase 3Gastric CancerOncologyDec 2026
NCT06685276SintilimabPhase 2Colorectal Cancer MetastaticOncologyDec 2026
NCT04331093SintilimabPhase 2Acral MelanomaOncologyDec 2026
NCT05512351SintilimabPhase 2OligodendrogliomaOncologyDec 2026
NCT06050317SintilimabPhase 2Pancreas CancerOncologyDec 2026
NCT05507632SintilimabPhase 2Unresectable Hepatocellular CarcinomaOncologyDec 2026
NCT05757336SintilimabPhase 2Gallbladder CancerOncologyDec 2026
NCT05171660SintilimabPhase 3Colorectal Cancer Stage IVOncologyDec 2026
NCT06314334SintilimabPhase 2Natural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeOncologyDec 2026
NCT05220267SintilimabPhase 2Non Clear Cell Renal CarcinomaOncologyDec 2026
NCT06031285SintilimabPhase 2Hepatocellular CarcinomaOncologyDec 2026
NCT05400070SintilimabPhase 2SintilimabOncologyDec 2026
NCT06391190SintilimabPhase 1Locally Advanced Cervical CarcinomaOncologyDec 2026
NCT06775743SintilimabPhase 2NSCLC (Advanced Non-small Cell Lung Cancer)OncologyDec 2026
NCT06812039SintilimabPhase 2Hepato Cellular Carcinoma (HCC)OncologyDec 2026
NCT07257653SintilimabPhase 2Colorectal NeoplasmsOncologyDec 2026
NCT04833387SintilimabPhase 2Colorectal CarcinomaOncologyDec 2026
NCT05481476SintilimabPhase 2Pancreatic NeoplasmsOncologyDec 2026
NCT07501351SintilimabPhase 2Hepatocellulcar CarcinomaOncologyDec 2026
NCT04836728SintilimabPhase 2Non-small Cell Lung Cancer MetastaticOncologyDec 2026
NCT07394387SintilimabPhase 2Triple Negative Breast Cancer (TNBC)OncologyDec 2026
NCT06341595SintilimabPhase 2Gastric CancerOncologyDec 2026
NCT06555471SintilimabPhase 2Gastric CancerOncologyDec 2026
NCT03950271SintilimabPhase 2Gastric CancerOncologyDec 2026
NCT04961515SintilimabPhase 2Primary Central Nervous System Hodgkin LymphomaOncologyDec 2026
NCT07852091SintilimabPhase 2Chronic Hepatitis BInfectious diseaseDec 2026
NCT06730373SintilimabPhase 2HER2-positive Gastric CancerOncologyDec 2026
NCT07468630SintilimabPhase 2Colon AdenocarcinomaOncologyDec 2026
NCT07468630SintilimabPhase 2Colon AdenocarcinomaOncologyDec 2026
NCT06013618SintilimabPhase 2NeuroblastomaOncologyDec 2026
NCT06494943SintilimabPhase 1Head and Neck CancerOncologyDec 2026
NCT05979818SintilimabPhase 1Non Small Cell Lung CancerOncologyDec 2026
NCT06742411SintilimabPhase 1Gastric (Stomach) CancerOncologyDec 2026

The 60 nearest readouts of 178 trials; the rest in the app.

Targets

CTLA4 (2) ERBB2 (1) PDCD1 (1) EGFR (1) MET (1) IL23A (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Beijing Biotech Johnson & Johnson (Janssen) Sichuan Baili Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Akeso Shenyang Sunshine Pharmaceutical Innovent Biologics (Suzhou)

Companies built like this

Lepu Biopharma R-Pharm Chipscreen Biosciences BeiGene mAbxience Research

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.